ESP Block vs. Traditional Pain Management for ERAS
Erector Spinae Plane Block Versus Traditional Pain Management for Enhanced Recovery After Surgery
1 other identifier
interventional
300
1 country
1
Brief Summary
Patients undergoing thoracotomy, thoracoscopy or other surgical procedures involving the integrity of the chest wall are always in a special point of interest of both surgical and anesthesiological specialities. Most of the patients will describe the pain after thoracic surgery as severe. It might lead to a number of serious complications: respiratory failure due to splinting; inability to clear secretions by effective coughing, with resulting pneumonia; and turning into a chronic pain: the post-thoracotomy pain syndrome. Traditional pain management in these groups of patients - such as opiate treatment, thoracic epidural analgesia, and non-opioid drugs - may have serious side effects. Large doses of opiates suppress the cough reflex and lead to respiratory depression with subsequent re-intubation and re-ventilation. Thoracic epidural analgesia, though being considered paramount among other analgesic options, requires a significant clinical experience. Still, it might be insufficient for satisfactory pain control and even complicated with pneumothorax, total spinal anaesthesia and inadvertent intravascular injection. Non-steroidal anti-inflammatory drugs (NSAIDs) and Tramadol are weak analgesics inadequate for severe pain control and might be responsible for gastrointestinal bleeding. We suggest performing erector spinae plane block for intraoperative and postoperative pain management due to the ease of use and better analgesic effect. What remains is hard proof for the clinical efficacy and safety of this block, followed by a demonstration of the uptake of it in the hands of non-regional anaesthetists.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3 postoperative-pain
Started Mar 2020
Typical duration for phase_3 postoperative-pain
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 5, 2020
CompletedStudy Start
First participant enrolled
March 5, 2020
CompletedFirst Posted
Study publicly available on registry
March 6, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 5, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
September 5, 2021
CompletedMarch 6, 2020
March 1, 2020
1 year
March 5, 2020
March 5, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Visual Analog Pain Score
Reported immediate postoperative VAS score, up to 3rd day
3 days
Total pain med consumption in the PACU
Total Morphine, NSAIDs and Tramadol amount (mg) in the PACU
3 hours
Length of stay in the PACU
Length of stay in postoperative care room
24 hours
Secondary Outcomes (2)
Length of hospital stay
30 days
Chronic pain development
6 months
Study Arms (6)
Thoracic surgery + ESPblock
EXPERIMENTALThoracic surgery + ESPblock + standard pain management
Abdominal surgery + ESPblock
EXPERIMENTALAbdominal surgery + ESPblock + standard pain management
Spinal surgery + ESPblock
EXPERIMENTALSpinal surgery + ESPblock + standard pain management
Thoracic surgery
NO INTERVENTIONThoracic surgery + standard pain management
Abdominal surgery
NO INTERVENTIONAbdominal surgery + standard pain management
Spinal surgery
NO INTERVENTIONSpinal surgery + standard pain management
Interventions
Erector spinae plane block
Eligibility Criteria
You may qualify if:
- all consecutive adult patients who undergo thoracic, spinal or abdominal surgery in Soroka Medical Center, and agree to participate in the study, older than 18 years, who meet criteria of ASA physical status I-II-III-IV class.
You may not qualify if:
- Unconscious or mentally incompetent patients or those who refuse to participate in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
SorokaUMC
Beersheba, Israel
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michael Dubilet, MD
Soroka University Medical Center
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr.
Study Record Dates
First Submitted
March 5, 2020
First Posted
March 6, 2020
Study Start
March 5, 2020
Primary Completion
March 5, 2021
Study Completion
September 5, 2021
Last Updated
March 6, 2020
Record last verified: 2020-03
Data Sharing
- IPD Sharing
- Will not share